for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Akari Therapeutics PLC (ADR)

AKTX.OQ

Latest Trade

2.20USD

Change

--(--)

Today's Range

--

 - 

--

52 Week Range

0.87

 - 

3.35

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
2.20
Open
--
Volume
--
3M AVG Volume
7.41
Today's High
--
Today's Low
--
52 Week High
3.35
52 Week Low
0.87
Shares Out (MIL)
2,872.90
Market Cap (MIL)
65.27
Forward P/E
-220.00
Dividend (Yield %)
--

Latest Developments

More

Aspire Capital Fund Reports 19.89% Passive Stake In Akari Therapeutics - SEC Filing

Akari Therapeutics Reports Qtrly Loss Per Share $0.00

Akari Therapeutics Announces Positive Topline Results From Phase II Study Of Nomacopan In Bullous Pemphigoid Patients

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Akari Therapeutics PLC (ADR)

Akari Therapeutics, Plc is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of treatments for a range of rare and orphan autoimmune and inflammatory diseases caused by dysregulation of complement component 5 (C5), including paroxysmal nocturnal hemoglobinuria, Guillain Barre syndrome and atypical Hemolytic Uremic Syndrome. The Company’s lead product candidate, nomacopan inhibits both terminal complement activation and leukotriene B4, or LTB4. It inhibits terminal complement activation by tightly binding to C5 and preventing its cleavage and activation by complement.

Industry

Biotechnology & Drugs

Contact Info

24 W 40th St Fl 8

NEW YORK, NY

10018-1028

United States

+1.646.3500702

http://akaritx.com/

Executive Leadership

Ray Prudo

Chairman of the Board

David Horn Solomon

Chief Executive Officer

Torsten Hombeck

Chief Financial Officer

Clive Richardson

Chief Operating Officer, Director

Nigel A.S. Hernandez

Vice President - Worldwide Regulatory Affairs

Key Stats

2.00 mean rating - 1 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2017

0.0K

2018

0.0K

2019

0.0K

2020(E)

0.0K
Price To Earnings (TTM)
--
Price To Sales (TTM)
--
Price To Book (MRQ)
35.44
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
0.00
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
-1,182.27
Return on Equity (TTM)
-191.13

Latest News

Latest News

BRIEF-Aspire Capital Fund Reports 19.89% Passive Stake In Akari Therapeutics - SEC Filing

* ASPIRE CAPITAL FUND LLC REPORTS 19.89% PASSIVE STAKE IN AKARI THERAPEUTICS PLC AS OF JULY 1 - SEC FILING Source text for Eikon: https://bit.ly/3eT7bFx Further company coverage:

BRIEF-Akari Therapeutics Appoints Chief Financial Officer

* AKARI THERAPEUTICS ANNOUNCES APPOINTMENT OF CHIEF FINANCIAL OFFICER

BRIEF-Akari Therapeutics Enters Into A Securities Purchase Agreement For Up To $30 Mln With Aspire Capital Fund

* AKARI THERAPEUTICS ENTERS INTO A SECURITIES PURCHASE AGREEMENT FOR UP TO $30 MILLION WITH ASPIRE CAPITAL FUND, LLC

BRIEF-Akari Therapeutics Reports Qtrly Loss Per Share $0.00

* AKARI THERAPEUTICS REPORTS FIRST QUARTER 2020 FINANCIAL RESULTS AND HIGHLIGHTS RECENT CLINICAL PROGRESS

BRIEF-Akari Therapeutics Receives Positive EMA Opinion On Orphan Designation For Nomacopan For Bullous Pemphigoid

* AKARI THERAPEUTICS RECEIVES POSITIVE EMA OPINION ON ORPHAN DESIGNATION FOR NOMACOPAN FOR BULLOUS PEMPHIGOID

BRIEF-Akari Therapeutics Announces Positive Topline Results From Phase II Study Of Nomacopan In Bullous Pemphigoid Patients

* AKARI THERAPEUTICS ANNOUNCES POSITIVE TOPLINE RESULTS FROM FULLY RECRUITED PHASE II STUDY OF NOMACOPAN IN BULLOUS PEMPHIGOID PATIENTS

BRIEF-Akari Reports Fourth Quarter Results

* AKARI THERAPEUTICS REPORTS FOURTH QUARTER AND FULL YEAR 2019 FINANCIAL RESULTS AND BUSINESS HIGHLIGHTS

BRIEF-Akari Therapeutics Plc Files Prospectus Relates To Resale, By Selling Shareholders Of Up To 765.6 Million Ordinary Shares

* AKARI THERAPEUTICS PLC FILES PROSPECTUS RELATES TO RESALE, BY SELLING SHAREHOLDERS OF UP TO 765.6 MILLION ORDINARY SHARES - SEC FILING Source text: (https://bit.ly/2UkMRF3) Further company coverage:

BRIEF-Akari Therapeutics Announces Private Placement

* AKARI THERAPEUTICS PLC - WILL ISSUE UNREGISTERED ADSS AT A PURCHASE PRICE OF $1.70 PER ADS Source text for Eikon: Further company coverage:

BRIEF-David Horn Solomon Resigns As CEO Of Akari Therapeutics

* AKARI THERAPEUTICS SAYS ON MAY 8, DAVID HORN SOLOMON, RESIGNED AS CEO AND AS A MEMBER OF BOARD EFFECTIVE IMMEDIATELY - SEC FILING

BRIEF-Akari Therapeutics Qtrly Loss Per Common Share $0.01

* AKARI THERAPEUTICS ANNOUNCES FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS AND HIGHLIGHTS RECENT CLINICAL PROGRESS

BRIEF-Akari Therapeutics Says Mid-stage Trial Of Coversin In Patients With Rare Blood Disease PNH Successful

* AKARI THERAPEUTICS ANNOUNCES PHASE II COBALT TRIAL OF COVERSIN™ IN PATIENTS WITH PNH MET THE PRIMARY ENDPOINT

BRIEF-Akari Therapeutics proposes public offering of ADS

* Akari Therapeutics announces proposed public offering of American Depositary Shares Source text for Eikon: Further company coverage:

BRIEF-Akari Therapeutics announces further clinical progress

* Akari Therapeutics - 3 additional patients have been enrolled in ongoing Phase II Cobalt clinical trial of Coversin in patients with PNH

BRIEF-Akari ‍plans to advance its lead drug, Coversin towards Phase III clinical studies in paroxysmal nocturnal hemoglobinuria in Q1 2018​

* plans to advance its lead drug, Coversin towards Phase III clinical studies in paroxysmal nocturnal hemoglobinuria in Q1 2018

BRIEF-Akari Therapeutics appoints David Horn Solomon as CEO

* Akari Therapeutics announces appointment of David Horn Solomon as CEO

BRIEF-Akari Therapeutics PLC files for mixed shelf of up to $100 mln

* Akari Therapeutics PLC files for mixed shelf of up to $100 million – SEC filing Source text: (http://bit.ly/2vLqRqG) Further company coverage:

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up